Supplementary Material

<b>Supplementary Table 1.</b> The transition pattern of the 7 common uremic indicators between case and control periods before hemodialysis initiation (N = 1,079). “No” means the indicator does not reach the predefined cutoff values shown on the first column, whereas “Yes” means the opposite. The order of these indicators follows the frequency of “no-to-yes” from high to low. <b>Supplementary Table 2. </b>Biochemical characteristics in control and case periods (N = 1,079) <b>Supplementary Table 3. </b>Distribution of 30-day and daily doses of furosemide in control and case periods and based on the three dialysis timing groups. <b>Supplementary Figure 1.</b> Flow diagram of patient selection. <b>Supplementary Figure 2.</b> Case-crossover study design and timing of exposure measurements including uremic indicators and medications in relation to hemodialysis initiation.

<b>补充表1</b> 本研究纳入1079例受试者，该表展示了血液透析启动前病例期与对照期内7项常见尿毒症指标的转归模式。“否”代表该指标未达到首列所示的预设临界值，“是”则代表与之相反的情况。各项指标的排列顺序按照“否转至是”的发生频率由高到低排序。<b>补充表2</b> 对照期与病例期的生化特征（N=1079）<b>补充表3</b> 对照期与病例期内，以及基于三种透析时机分组的呋塞米（furosemide）30日剂量与每日剂量的分布情况<b>补充图1</b> 患者筛选流程示意图<b>补充图2</b> 病例交叉研究设计方案，以及与血液透析启动相关的尿毒症指标与药物暴露测量时点